Article
Professor van Vollenhoven has compiled a state-of-the-art review on lupus treatment advances – current and future. SLE management is entering an unprecedented phase.
Dr. John Cush
Tweet
Prospective RCT of 39 refractory carpal tunnel pts (63 wrists) were injx w/ 1) US hydrodissection w/ normal saline (NS); 20 steroid injx; 3) US saline + steroid. Wk 24: Improved 86% & 90% grps 1 & 3; Saline superior to steroid; & adding steroid to NS yielded no benefit https://t.co/vCAB7Hojlo
Dr. John Cush
Tweet
Thai study of opportunistic infx in Pediatric SLE - 177 pSLE, & 38 developed OI (3.4/100PY). Most common OIs: Candida (27%), Aspergillus (13.5%), CMV (13.5%) - lung & skin mostly. Risk factors: Pulse steroids, Dz activity (SLEDAI-2K ≥11) https://t.co/0zjDOnDCEh https://t.co/H7JZ56ItDY
Dr. John Cush
Tweet
On this week's podcast, Dr. Jack Cush reviews the news: Steroids are easy to start and hard to stop; hold the MTX but not the biologic or JAK, weighing in on avacopan, and age-old messages for old-age patients.
🎧 Read + listen: https://t.co/kK8WKgIxYT and subscribe wherever you https://t.co/xGTXyuRJU8
Dr. John Cush
Tweet
Steroids are easy to start and hard to stop. Hold the MTX, but not the biologic or JAK. And what’s the latest on avacopan?
This week, Dr. Jack Cush reviews the rheumatology news you don’t want to miss: from new approvals and promising trial results to sobering Sjögren’s data, https://t.co/UC4RdHMaFS
Article
On this week's podcast, Dr. Jack Cush reviews the news: Steroids are easy to start and hard to stop; hold the MTX but not the biologic or JAK, weighing in on avacopan, and age-old messages for old-age patients.
Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Dr. John Cush
Tweet
Prednisone Primer for Patients
The Washington Post published a patient overview on "what Prednisone does to your body".
Prednisone is a double-edged drug. It has been on the market since 1955, ranks among the 40 most-prescribed US drugs, and about 10 million Americans receive
Article
The Washington Post published a patient overview on "what Prednisone does to your body".
Dr. John Cush
Tweet
Residual steroids doesnt preserve remission. Japan FRANK #RA registry 411/3,863 were in Boolean remission - 130 on GC vs 231 non-GC (1/3 on b/tsDMARDs). Roughly 1/3 flared to LDA @12 mos. Outcomes same for GC vs non-GC Rx pts. https://t.co/xPctEjFCLT https://t.co/YIHFaQkzeO
Article
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Dr. John Cush
Tweet
Indian Single center retrospective study of 28 children ≤18 yrs tested w/ 18F-FDG-PET/MR for pyrexia (PUO). 25% Dx w/ pre-stenotic TAKayasu (mean 13.9 yrs), & 20/21 alternative Dxs. All had Sxs & high ESR/CRP; all Rx w/ GC & MMF, 3 w/ biologics https://t.co/6trs1WssjW https://t.co/EOPIarRhY5
Article
A real world analysis of drug use in giant cell arteritis (GCA) patients shows that despite intending to taper patients off glucocorticoids (GC) by 24 months, 75% remained on GCs for ≥ 48 months.
Article
As GLP-1/GIP receptor agonists become standard co-management tools for obese patients with RA, PsA, axSpA, and gout, this JAMA Insights perspective by Kushner, et al. reframes lifestyle counseling as an adjunct to pharmacotherapy - a reversal of the traditional model. This has with direct
Dr. John Cush
Tweet
Added IVIG is Effective in Myositis
A small randomized controlled trial demonstrates that intravenous immunoglobulin (IVIG) added to cortocosteroids lead to greater and faster improvements in patients with newly diagnosed IIMs.
https://t.co/XLrvLSoOic https://t.co/xhjPBXLxiC
Dr. John Cush
Tweet
Added IVIG is Effective in Myositis
A small randomized controlled trial demonstrates that intravenous immunoglobulin (IVIG) added to cortocosteroids lead to greater and faster improvements in patients with newly diagnosed idiopathic inflammatory myopathies (IIMs). https://t.co/uNNJ9sHU8M
Dr. John Cush
Tweet
Single center study of FALLs in 124 ambulatory RA females ≥50 yrs.(age 68 yrs, DAS28 2.6, sarcopenia 16%, prior fall 25%). 27.4% had falls; predicted by prior fall hx (OR 2.76, hypnotics/anxiolytics (3.92), not steroids or sarcopenia (NS trend) https://t.co/J62RPF9rQs https://t.co/OKxdPl5Oev
Article
Smolen, Kerschbaumer, Aletaha, and Robinson have published a comprehensive review article of rheumatoid arthritis (RA) in JAMA, noting significant changes to our understanding and treatment guidelines.
Dr. John Cush
Tweet
The global inflammatory myopathies market size was valued at USD 1.81 billion in 2025 and is expected to reach USD 2.67 billion by 2033 (CAGR of 5.00%). This applies to: Polymyositis, Dermatomyositis, Inclusion Body Myositis, Juvenile Myositis, Corticosteroids, https://t.co/vb7zfM76pO
Article
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. Take this week's RheumIQ and test your knowledge!
Article
Polymyalgia rheumatica (PMR) is a common disorder of the elderly that responds well to glucocorticoids (GC), but is plagued by an inability to wean off of GCs.
Article
A secondary analysis of the VALOR trial has shown that the TYK2/JAK1 inhibitor brepocitinib was effective at cutaneous disease activity outcomes, delivering rapid, clinically meaningful, and remission-level control of cutaneous dermatomyositis (DM).
Article
A EUVAS-sponsored expert panel of 37 specialists across rheumatology, nephrology, dermatology and pathology has published evidence-based guidelines for adult-onset IgA vasculitis (IgAV), which behaves very differently in adults compared to usually self-limited childhood form.
Article
This review article addresses the recognition, prevention and management of glucocorticoid toxicity in rheumatic patients.
Dr. John Cush
Tweet
French study of 90 RA F pts w/ 100 pregnancies (steroids 46% & biologics 39% were used). Vs 359 controls, RA had signif. more preterm birth (PTB;OR 2.08) & small for gestational age. SGA assoc w/ nulliparity (adj OR 4.38), PTB assoc w/ maternal age (aOR 1.14) & GC ≥10 mg/d (aOR https://t.co/StCJW2rsZI
